Outcome 3: Oral HIV PrEP as part of a combined prevention package delivered safely for female sex workers Four randomized controlled trials have demonstrated that daily, oral PrEP is safe for HIV-uninfected women in a wide range of settings; these antiretrovirals have been proven safe for HIV-infected women for many years of use. The most common side effects of FTC/TDF are minor and short-lived (i.e. first several weeks). This study will provide evidence for the safe delivery of oral PrEP to female sex workers in brothel and street-based settings in India. Quarterly clinic visits will assess physical health, side effects, adverse events and any other social harms or concerns with PrEP use. This study will invest in continuous engagement with communities of female sex workers according to good participatory practice guidelines to provide correct information about PrEP, keep communities continuously engaged, and maintain adherence to PrEP.